Episode 60
Biotech Hangout
00:00
Haudafne: A Mixed Profile
The drug has a widely agreed mixed profile. The FDA here, at least in the review documents where the stock was down about 30%, took a more aggressive view and concerning view around the safety. And so there's some fatality rates and liver injury predicted rates for intercept versus other drugs. I've never seen this put together and presented like intercept would have done it.
Play episode from 22:38
Transcript
